Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...

Over 35 years ago, a group led by Dr. Lowy contributed to the early studies that identified RAS as a cancer-causing gene and helped explain how it promotes tumor growth. In this new study, the ...

It causes mutations in the p53 tumor-suppressor gene as well as ras mutations ... They state, "In lung cancer p53 mutations have been found in 56% of tissue samples, and in colorectal, esophageal ...

For instance, growth-promoting genes, such as the gene for the signaling protein Ras, are among those most commonly mutated in cancer cells, becoming super-active and producing cells that are too ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease. This unexpected discovery could help doctors identify which ...

There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf ...

Although many of the genes involved in cancer have now been identified ... small GTPase proteins and are mutated in lung adenocarcinoma and in the germline of “Ras-opathy” patients. Although KRAS has ...

RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key drivers of some of the ...